PRP & PRF combined with Autologous Fibroblast Cell

FIBROCELLplus produced on the same production platform with FIBROCELL®, combined with Platelet rich plasma, is an autologous cellular treatment method used for the treatment of festering chronic sores (diabetes, compression, venous ulcer, polyarteritis nodosa etc.) and burns.
FIBROCELLplus includes platelet-rich plasma obtained from one’s own blood, as well as the own fibroblast cells of the recipient’s primary cells of the connective tissue.

Treatment Principle

  • These two separate autologous components are produced and assembled with a specific protocol.
  • FIBROCELLplus® is applied to an unhealed chronic wound to initiate the epithelialization and regeneration process there.
  • FIBROCELLplus® supports the granulation texture by providing a natural way to form the dermis skeleton.

* FIBROCELLplus belongs to DOKU BİYOTEKNOLOJİ C0.LTD., and it is PRP product combined with the first and only patented autologous fibroblast cell in Turkey

Advantages of FIBROCELLplus

  • It is obtained from the individual’s own tissue and plasma (autologous) without having side effects.
  • Biocompatible, natural, and does not contain synthetic or chemical components. Therefore, it also reduces the formation of scar tissue.
  • It does not contain animal (cattle, pig, etc.) components.
  • It works in harmony with collagen, PGLA or hyaluronic acid based sponge, membrane or gel form biomaterials and it enhances their effects.
  • It consists of 3 repeated applications so, it supports wound healing process.

Click for case examples. (Preparation)

Click for brochure. (Preparation)

Scientific Studies

1- Roubelakis,  M.G., et al. Platelet-Rich Plasma (PRP) Promotes Fetal Mesenchymal Stem/Stromal Cell Migration and Wound Healing Process. Stem Cell Rev. and Rep . 10: 417–428, 2014.

2- Alsousou, J., et al. The role of platelet-rich plasma in tissue regeneration. Platelets, 24:3, 173-182, 2013.

3- Scuderi, N.,  Anniboletti T. Clinical Application of Autologous Three-cellular Cultured Skin Substitutes Based on Esterified Hyaluronic Acid Scaffold: Our Experience.. In vivo  2009; 23: 991-1004.

4- O’Connell, S.M., et al. Autologous platelet-rich fibrin matrix as cell therapy in the healing of chronic lower-extremity ulcers. Wound Repair and Regeneration. 16: 749-756, 2008.

5- Choukroun, J., et al. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part IV: Clinical effects on tissue healing. Oral Radiol Endod. 101: 56-60, 2006.

6- Ludena, D., et al. Cell culture in autologous fibrin scaffolds for applications in tissue engineering.  Experimental Cell Research.  322: 1-11, 2014.

7- Sood R, Roggy D, Zieger M, Balledux J, Chaudhari S, Koumanis DJ, Mir HS, Cohen A, Knipe C, Gabehart K, et al. Cultured epithelial autografts for coverage of large burn wounds in eighty-eight patients: the Indiana University experience. J Burn Care Res 2010; 31: 559-68.

8-Erdag G, Sheridan RL. Fibroblasts improve performance of cultured composite skin substitutes on athymic mice. Burns 2004; 30: 322-8

9- Morimoto N, Saso Y, Tomihata K, Taira T, Takahashi Y, Ohta M, Suzuki S. Viability and function of autologous and allogeneic fibroblasts seeded in dermal substitutes after implantation. J Surg Res 2005; 125: 56-67.

10-El-Ghalbzouri A, Gibbs S, Lamme E, Van Blitterswijk CA, Ponec M. Effect of fibroblasts on epidermal regeneration. Br J Dermatol 2002; 147: 230-43.

11-You HJ, Han SK, Lee JW, Chang H. Treatment of diabetic foot ulcers using cultured allogeneic keratinocytes: a pilot study. Wound Repair Regen 2012; 20: 491-9.

12-Han SK, Choi KJ, Kim WK. Clinical application of fresh fibroblast allografts for the treatment of diabetic foot ulcers: a pilot study. Plast Reconstr Surg 2004; 114: 1783-9.

13- Han SK, Kim WK. Revisiting fresh fibroblast allograft as a treatment for diabetic foot ulcers. Plast Reconstr Surg 2009; 123: 88e-9e.

Han SK, Kim HS, Kim WK. Efficacy and safety of fresh fibroblast allografts in the treatment of diabetic foot ulcers. Dermatol Surg 2009; 35: 1342-8.

15- Choi J, Minn KW, Chang H. The efficacy and safety of platelet-rich plasma and adipose-derived stem cells: an update. Arch Plast Surg 2012; 39: 585-92.

16- Jeong SH, Han SK, Kim WK. Treatment of diabetic foot ulcers using a blood bank platelet concentrate. Plast Reconstr Surg 2010; 125: 944-52.

17- Han SK, Kim DW, Jeong SH, Hong YT, Woo HS, Kim WK, Gottrup F. Potential use of blood bank platelet concentrates to accelerate wound healing of diabetic ulcers. Ann Plast Surg 2007; 59: 532-7.

18- Nurden AT, Nurden P, Sanchez M, et al. Platelets and wound healing. Front Biosci 2008;13:3532–48.

19- Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev. 2009;23(4):177–89.

20- Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler ELL. Classification and treatment of chronic nonhealing wounds: successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg 1986; 204: 322–30.

21- McAleer JP, Sharma S, Kaplan EM, Perisch G. Use of autologous platelet concentrate in a nonhealing lower extremity wound. Adv Skin Wound Care 2006; 19: 354–63.

22- Mazzucco L, Medici D, Serra M, Panizza R, Rivara G, Orecchia S, Libener R, Cattana E, Levis A, Betta PG, Borzini P. The use of autologous platelet gel to treat difficult to heal wounds: a pilot study. Transfusion 2004; 44: 1013–8.

23- Gosch C, Zeichner A, Carroll R, Bois J. Evaluation of an autologous platelet rich fibrin matrix technology for diabetic foot ulcer treatment. Wound Rep Regen 2007; 15: A38.

24- O’Connell SM, Impeduglia T, Hessler K, Wang X-J, Carroll RJ, Dardik H. Autologous platelet-rich fibrin matrix as a stimulator of healing of chronic lower extremity ulcers. Wound Rep Regen 2006; 14: A76.

25- Boyce ST, Kagan RJ, Meyer NA, Yakuboff KP and Warden GD: Cultured skin substitutes combined with Integra to replace native skin autograft and allograft for closure of full-thickness burns. J Burn Care Rehabil 20(6): 453-461, 1999. Comment in: J Burn Care Rehabil 22(2): 197-198, 2001, J Burn Care Rehabil 22(2): 198-199, 2001.